FEATURED POST
What You Can Learn from 7 Theme Fusion Success Stories
Nam lacinia arcu tortor, nec luctus nibh dignissim eu. Nulla sit amet maximus nulla. Pellentesque a accumsan eros, ac molestie nulla. Morbi interdum in neque vitae vulputate.
CVBF’s Expertise in Phase I Clinical Trials: A Commitment to Excellence
Phase 1 trials, be they conducted on healthy volunteers or patients, focus on generation of initial knowledge on tolerability, safety and PK/PD.. [...]
Unveiling the New and Improved Website
In today's fast-paced digital world, a company's online presence is often its first point of contact with customers. It's not just a [...]
A short history of CVBF
We are thrilled to invite you to watch the CVBF History Timeline Video to have a glimpse of our journey through the [...]
CVBF spotlight on scientific literature: “Why children have to wait years for new drugs”
This recent article is part of Nature Outlook: Children‘s health and focuses on the lack of medicines approved for paediatric [...]
First gene therapy to treat haemophilia B
EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Hemgenix (etranacogene dezaparvovec), the the first [...]
Event: The next steps for a real European Health Union – Delivering patient care through digital solutions
This in-person event, organized by the European Association of E-Pharmacies (EAEP) will be held on Thursday, 27 October at TownHall [...]
CVBF participates in the Smarter Programme For Technological Innovation
Thanks to the close collaboration with Aldo Moro University of Bari, Exprivia spa and Hero srl, and following the agreement signed [...]
Share4Brain Project’s meeting in Athens
The Share4Brain Project meeting was held on 23-24 of September 2021 at Amarilla hotel in Athens, Greece. Greek policymakers such as MEP Stelios Kymporopoulos, the member of [...]
NeoVanc Project Article published in the LANCET Child & Adolescent Health Journal
The NeoVanc Project article Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial was published in the Lancet Child [...]
Kids suffer serious adverse reactions in AGTC gene therapy trial
Applied Genetic Technologies Corporation has run into safety problems after escalating the dose in its paediatric gene therapy trial. Sixty percent of subjects in the [...]
My Clinical Trial Center serious videogame
The iCAN groups KIDS Albania and KIDS Bari, with the support of CVBF and TEDDY Network, have created a brand-new serious game: My Clinical Trial Center (My [...]
Newsletter, MAY 2021
31st May 2021 Newsletter May 2021 CVBF CRO Services designed for your Clinical Trial! CVBF is a self-certified Contract Research Organisation (CRO) at [...]
Newsletter, MARCH 2021
30th March 2021 Newsletter March 2021 The recent approval by regulatory agencies worldwide of Zolgensma, a gene therapy for children with type 1 Spinal [...]